InventisBio Co

InventisBio Co Debt/EBITDA

Total Debt to EBITDA Ratio of InventisBio Co (688382.SS) as of Nov 20, 2026.

Debt/EBITDA

0.00

Last updated:

Total Debt to EBITDA Ratio of InventisBio Co is 2025 0.00 . Total Debt to EBITDA Ratio of InventisBio Co was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InventisBio Co Stock analysis

What does InventisBio Co do? InventisBio Co Ltd, headquartered in Shanghai, China, operates in the Health Care sector within the Biotechnology industry. The company employs 222 full-time staff and completed its IPO on July 25, 2022. InventisBio focuses on drug research and development for major diseases including tumors and metabolic conditions. Its core products under clinical development include D-0120, D-0502, D-1553, and BPI-D0316, targeting oncology and metabolic disease areas. InventisBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InventisBio Co stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio InventisBio Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's InventisBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — InventisBio Co

All Key Metrics — InventisBio Co